Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Israel / NCT06096831
Enrolling by invitation Observational

Living With Stroke - Sustainable Utilization of Healthcare Services

NCT06096831 · tracked via the Priya Life Science Israel tracker
Phase
Observational
Started
2023-11-15
Last updated
2025-12-16

Condition(s) studied

StrokeCerebrovascular DisordersCerebrovascular AccidentHealthcare Utilization

Study summary

The proposed study will generate a national mapping of healthcare utilization patterns in people post-stroke in the chronic phase living in the community; examine the associations between individual-level characteristics, health outcomes and healthcare utilization; and will describe patients' perspectives on their needs for health services and their experiences of using them.

The study will use mixed-methods methodology (quantitative and qualitative) and will proceed in three parts. In part 1, data will be extracted retrospectively from electronic medical records of of Clalit Health Services, covering all patients with a stroke diagnosis. In part 2, a sub-sample of 240 patients will be asked to answer standardized questionnaires. In part 3, a sub-sample of 20 participants will participate in in-depth, semi-structured interviews.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria for the retrospective study (Part 1): * People diagnosed with stroke (First stroke occurred between 2010-2022) * At least one year after the event * Living in the community * Aged 18 and above * Insured by HMO (Clalit health services) Exclusion Criteria for the retrospective study (Part 1): * Stroke chronicity of less than a year * Diagnosis of TIA (Transient Ischemic Attack) Inclusion Criteria for the cross-sectional and qualitative study (Parts 2\&3): * People diagnosed with stroke * Hospitalized for a first stroke at the 'Carmel' Medical Center between 2010-2022 * Understand Hebrew/ Arabic/ Russian in a way that allows them to understand the consent form and answer the survey questions. Exclusion Criteria for the cross-sectional and qualitative study (Parts 2\&3): * Stroke chronicity of less than a year the study * Transient ischemic attack (TIA) * Patients who have a guardian, a nursing condition as a result of diseases other than stroke or other serious background diseases that impair function, people with communication difficulties that do not allow answering questionnaires or to be interviewed.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Haifa Haifa Israel

More University of Haifa trials in Israel

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06096831 on ClinicalTrials.gov ↗ ← All trials in Israel